Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

A. Magnan (1) , A. Bourdin (2, 3) , C-M Prazma (4) , F.C. Albers (4) , R-G Price (5) , S. Yancey (4) , H. Ortega (4)

1 ITX - ITX - unité de recherche de l'institut du thorax
2 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
3 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
4 GSK - GlaxoSmithKline [Research Triangle Park]
5 GSK, Uxbridge, Middlesex, UK.

Mots clés: omalizumab; severe eosinophilic asthma; mepolizumab

Domaines: Sciences du Vivant [q-bio]

A. Magnan, A. Bourdin, C-M Prazma, F.C. Albers, R-G Price, et al.. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy, 2016, 71 (9), pp.1335 - 1344. ⟨10.1111/all.12914⟩. ⟨hal-01785638⟩